Vector Biopharma Logo

Pioneers in delivering medicines of the future



Vector BioPharma is a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery, to improve treatments for patients. Incorporating cutting-edge platform technologies, from world-class academic research at the University of Zürich, Vector BioPharma uses engineered virus-like particles to achieve cell- and tissue-specific delivery, and tunable expression of genes and regulators with unprecedented precision.

Our Mission

We develop next-generation therapeutics using our proprietary platform that delivers the right gene to the right place at the right time with unparalleled precision and versatility.


Vector BioPharma’s cutting-edge gene precision delivery technology will transform the safety, efficacy, and specificity of biologics and cell therapies.

Our Shielded, Retargeted Adenovirus-based virus-like particle (SHREAD) platform utilizes a high capacity non-viral particle combined with exogenous, high-avidity adapter proteins to redirect delivery of DNA encoding therapeutics to defined biomarkers on the target cell or tissue, in a highly controlled manner.

This allows for the local production of highly potent drugs with greatly reduced risk of systemic toxicities and opens the door for multiple applications in gene-based medicines.


Vector BioPharma is a pharmaceutical company developing its own therapeutic products. The Company’s proprietary delivery technology is available to license by innovative companies with new modalities.

We are looking to partner with pioneers in the fields of immuno-oncology, cell therapies, precision medicine, and academic researchers to revolutionize gene delivery.


Vector BioPharma will commercialize its technology via the development of therapeutics and is initially focused on immuno-oncology. The company’s SHREAD technology can be used to deliver genes and gene regulators to facilitate the use of next-generation treatment modalities working with DNA, including in-situ expression of immune checkpoint inhibitors and CAR T cell therapies.

Following a successful Series A round in 2021, Vector Biopharma will continue to invest in technology development. We welcome inquiries from investors for series A extension as well as a future Series B investment round.



Vector BioPharma values diversity and inclusion and is committed to supporting its team’s personal and career development. If you’d like to find out more about career opportunities at Vector BioPharma, access our current vacancies through our partner’s hiring portal.


Founded in 2021, Vector BioPharma is headquartered in Basel, Switzerland. Situated at the very heart of Europe, bordering France and Germany, Basel boasts diversity, great quality of life and one of the largest pools of pharma talent.


Vector BioPharma AG
Aeschenvorstadt 36
4051 Basel, Switzerland